A Phase IIIb, Open, Randomised, Multicentre, Primary Study in Healthy Children, to Establish the Non-inferiority of GlaxoSmithKline (GSK) Biologicals' MeMuRu-OKA Vaccine (Administered at 9 and 15 Months of Age) Versus Priorix™ (9 Months of Age) and Priorix™ Co-administered With Varilrix™ at 15 Months of Age (Comparator) and Also to Evaluate the Non-inferiority of Priorix™ (9 Months of Age) and MeMuRu-OKA Vaccine (15 Months of Age) Versus the Comparator, All Administered Subcutaneously as Two-dose Primary Vaccination Course
Latest Information Update: 18 Jul 2023
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine; Varicella zoster virus vaccine live
- Indications Measles; Mumps; Rubella; Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 18 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 28 Jan 2011 Planned end date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov
- 31 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India.